Modality
siRNA
MOA
Menini
Target
VEGF
Pathway
Checkpoint
Crohn's
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Jul 2028
Phase 1Current
NCT07785814
318 pts·Crohn's
2020-04→2028-07·Terminated
318 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-062.3y awayInterim· Crohn's
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Termina…
Catalysts
Interim
2028-07-06 · 2.3y away
Crohn's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07785814 | Phase 1 | Crohn's | Terminated | 318 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |